Pathway Genomics vs Cradle
Side-by-side comparison of AI visibility scores, market position, and capabilities
CAP- and CLIA-accredited clinical genetic testing lab offering cancer risk, cardiac, pharmacogenomics, and wellness panels to physicians and patients; privately held, San Diego, founded 2008.
About
Pathway Genomics (also known as Pathway OME) is a privately held clinical genetic testing company founded in 2008 and headquartered in San Diego, California. The company operates a CAP-accredited and CLIA-certified clinical laboratory that provides physicians and patients with actionable, precision healthcare information derived from genetic analysis. Pathway's testing services cover cancer risk assessment, cardiac health, pharmacogenomics (drug response), inherited disease risk, nutrition and exercise response, and reproductive health — enabling personalized healthcare decisions grounded in genetic data.
AI protein design platform combining language models with lab automation; active learning cycles for enzyme, antibody, and therapeutic protein engineering optimization.
About
Cradle is a protein design platform using AI to help biotechnology and pharmaceutical companies engineer better proteins — enzymes, antibodies, and therapeutic proteins — with improved stability, activity, and manufacturability. Founded in 2021 and headquartered in Amsterdam with teams in San Francisco, Cradle raised approximately $24 million and targets biopharmaceutical, agricultural, and industrial biotechnology companies that need to engineer proteins with specific functional properties.
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.